Monday, October 26, 2020
11:00 a.m.–12:00 p.m. ET
The COVID-19 pandemic highlights the importance of a flexible and rapid response to real-time development of medical countermeasures for life-threatening viral pathogens. Using human B cells from survivors are a potential source of therapeutic antibodies, Dr. Carnahan will describe the pandemic response platform developed and deployed at the Vanderbilt Vaccine Center that has led to a large panel of anti-viral antibodies directed at SARS-CoV-2, including several antibodies currently in advanced clinical development.
Access recording here.
Speakers:
Robert Carnahan, Ph.D.
Associate Director, Vanderbilt Vaccine Center
Associate Professor, Pediatrics and Radiology and Radiologic Sciences
Vanderbilt University Medical Center
Director, Bioexpression and Fermentation Facility
Director, Master of Biomanufacturing and Bioprocessing
University of Georgia
